LY 178002 is a potent inhibitor of5-lipoxygenase (5-LPO),phospholipaseA2, withIC₅₀of 0.6 μM for 5-lipoxygenase, inhibits cellular production of LTB4 by human polymorphonuclear leukocytes, and shows relatively weak inhibition oncyclooxygenase.

LY178002 inhibits the generation of LTB4, PLA2 and FCO with IC₅₀s of 0.1, 6.3 and 4.2 μM^[1].

LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81%, and inhibits bone damage in rats. The minimum effective dose for LY178002 is 10 mg/kg p.o. In the established FCA model LY178002 at 50 mg/kg p.o. inhibits the uninjected paw swelling by 75%^[1].

319.46

C₁₈H₂₅NO₂S

107889-32-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.